IMMUNEONCO-B (01541) has completed the issuance of a total of 24.2 million shares of placement shares.
Yimingangke-B (01541) announced that all the conditions set out in the subscription agreement have been satisfied and the delivery has been made in accordance with the distribution...
IMMUNEONCO-B (01541) announced that all the preconditions set out in the subscription agreement have been met and the delivery has been settled on October 16, 2025, in accordance with the terms and conditions of the subscription agreement.
According to the terms and conditions of the subscription agreement, the placement agent has successfully placed a total of 24.2 million shares at a subscription price of HK$14.50 per share to no fewer than six subscribers, representing approximately 5.94% of the Company's issued share capital and approximately 6.11% of the issued H shares immediately prior to delivery, as well as approximately 5.61% of the Company's issued share capital and approximately 5.76% of the issued H shares after the issuance and placement of the shares.
Related Articles
.png)
Ningbo David Medical Device (300314.SZ) has obtained the first-class medical device registration certificate.

Focus on the demand for parent-child interaction, HAIDILAO (06862) has created its first family-friendly store with a panoramic "eat, drink, play, and have fun" experience.

Sunflower Pharmaceutical Group (002737.SZ): Pediatric pulmonary heat cough and wheezing oral solution approved for clinical trials.
Ningbo David Medical Device (300314.SZ) has obtained the first-class medical device registration certificate.
.png)
Focus on the demand for parent-child interaction, HAIDILAO (06862) has created its first family-friendly store with a panoramic "eat, drink, play, and have fun" experience.

Sunflower Pharmaceutical Group (002737.SZ): Pediatric pulmonary heat cough and wheezing oral solution approved for clinical trials.
